Guggenheim initiated coverage on Sionna Therapeutics with a new price target
$SION
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $45.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2025 | $45.00 | Strong Buy | Raymond James |
| 9/3/2025 | $22.00 | Sector Perform | RBC Capital Mkts |
| 3/4/2025 | Buy | TD Cowen | |
| 3/4/2025 | $32.00 | Buy | Stifel |
| 3/4/2025 | $45.00 | Buy | Guggenheim |
Raymond James initiated coverage of Sionna Therapeutics with a rating of Strong Buy and set a new price target of $45.00
RBC Capital Mkts initiated coverage of Sionna Therapeutics with a rating of Sector Perform and set a new price target of $22.00
TD Cowen initiated coverage of Sionna Therapeutics with a rating of Buy
Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 stabilizers restored the half-life of F508del-CFTR up to wild-type levels WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced data presented at the 2025 North American Cystic Fi
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced initiation of the PreciSION CF Phase 2a proof-of-concept (POC) trial evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when added to Trikafta® (elexacaftor/tezacaftor
WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that data will be presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington on October 22-25, 2025. Details of the presentation and posters are as follows: Title: Safety, tolerability, and pharmacokinetics of novel NBD1 stabilizers SION-719 and SION-451 from two phase 1 first-in
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer (CBO). "We are delighted to welcome Caroline to our executive team at such a pivotal stage for Sionna," said Mike Cloonan, President and Chief Executive Officer of Sionna. "Caroline's exceptional experience, leadership, and value creation mindset will
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial Next trials to initiate in the second half of 2025 with topline data expected in mid-2026 Sionna to hold a conference call today at 8:00 a.m. ET WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revo